New combo aims to control lung cancer that returns after standard therapy

NCT ID NCT04892953

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This phase II trial tests whether adding local treatments like surgery or radiation to the immunotherapy drug durvalumab can help control stage III non-small cell lung cancer that has progressed after chemoradiation and durvalumab. About 51 participants with 3 or more growing tumors will receive the combination. The goal is to see if this approach can delay further cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Durvalumab (immunotherapy) plus local therapy (surgery or radiation)
What this could lead to
If successful, this approach could offer a way to control advanced lung cancer that has started to grow again after initial treatment.
What could go wrong
This is a small, early-phase trial with only 51 participants, so results may not apply broadly. The combination may cause side effects or not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE III LUNG CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.